Altimmune's $225 Million Capital Raise Extends Runway Through Pivotal MASH Trial Readout

Altimmune strengthens balance sheet with $225M equity raise, funding MASH drug through 2029 data readout; shares jump 10% as Goldman Sachs upgrades to Neutral.

Altimmune has dramatically strengthened its balance sheet, pulling in $225 million through an oversubscribed equity offering that pushes its pro-forma cash position to roughly $400 million. The injection buys the biotech group critical time to advance its lead candidate, Pemvidutide, through the high-stakes final phase of clinical development.

Shares responded with a sharp rally, climbing more than 10 percent to €2.46 in European trading. The move still leaves the stock trading at a deep discount to its 52-week peak of €5.13, however, and the year-to-date performance remains underwater at roughly minus 15 percent.

The fresh capital extinguishes lingering doubts about Altimmune's ability to fund operations through the completion of its Phase 3 study in metabolic dysfunction-associated steatohepatitis, or MASH. With an annual cash burn rate hovering around $78 million, the company now has visibility stretching to the expected data readout in 2029. Management has signaled that the definitive trial is slated to kick off in the second half of 2026.

Goldman Sachs responded to the financing news by upgrading its rating on Altimmune from "Sell" to "Neutral," setting a price target of $2.50. The move reflects a reassessment of the risk profile now that the balance sheet is fortified.

In a separate signal of alignment with shareholder interests, several board members received grants of 48,800 stock options each, priced at $2.82 and subject to multi-year vesting restrictions. The options carry a ten-year term, tying executive incentives to long-term value creation.

The capital raise comes amid a broader wave of financing activity across the biotech sector, as developers rush to move promising metabolic and autoimmune candidates from mid-stage trials into pivotal studies. Large pharmaceutical companies have been active acquirers in the space, with several multi-billion-dollar deals closing in recent months.

All eyes now turn to the upcoming first-quarter earnings report, which will provide the first financial snapshot since the equity offering. For Altimmune, the path forward hinges on executing the Phase 3 timeline without delays. A successful data readout could position Pemvidutide as a serious contender in the increasingly crowded metabolic disease market.